



presents

# Redensity [II] Eyes Innovation in eye circle treatment

As experts in aesthetic medicine and specialising in creating and manufacturing hyaluronic acid dermal fillers implants, Teoxane Laboratories has continued to develop its range of injectables with a product specially designed and developed for eye circle correction. Known for its complexity, the difficult-to-treat eye circle area, with a lack of dedicated products, has rarely been considered until now. The Laboratories' R&D Department, as well as many clinical experts, have been collectively concentrated in their research for a suborbital area treatment. Today, Teoxane Laboratories have the pleasure to present the result of this extensive development process: a unique hyaluronic acid-based gel responding to the specifics of this anatomical area.

# **EYE CIRCLE CORRECTION**

#### A major concern for women...

In a recent study carried out by the Arcane Research Institute <sup>(1)</sup>, eyes and in particular eye circles, appear to be the most significant aesthetic concern for women: from the age of 30, nearly half of them rank this area first among their aging problems. «I look sad », «I look tired », «I look as if I haven't slept» these women confide to their physicians. However, aesthetic intervention in this area is not very common: the same study shows that this is only ranked 7<sup>th</sup> amongst of the most performed common aesthetic procedures.

#### ....A complex medical procedure

The periorbital area and particularly the suborbital area are both very fragile and specific in their characteristics, therefore any medical procedure must comply with several key steps: good anatomical knowledge of the periorbital area, a thorough diagnosis of the problem area and training in injection techniques in order to obtain the best aesthetic results.

# Redensity [II] Eyes



# **TEOXANE INNOVATION**

# A unique formulation specifically designed for eye circles

### A TARGETED INDICATION

Redensity [II] Eyes gel is indicated for eye circle treatment and in particular, for:

- Dark hollow circles
- Tear trough
- Palpebromalar groove
- Minimal palpebral or malar bags

## A UNIQUE FORMULATION

Redensity [II] Eyes has been developed thanks to an innovative production process resulting in a subtle balance between a 15mg/g concentration level of hyaluronic acid and a semi-crosslinking process (a combination of cross-linked\* and non-crosslinked hyaluronic acid). This characteristic implies controlled risk of swelling with very low risk of oedema (2).







- → A low hygroscopic activity: 15mg/g hyaluronic acid concentration level combined with a crosslinked process (a combination of crosslinked and non-crosslinked hyaluronic acid) produces a low-hygroscopic gel. This characteristic allows controlling the risk of swelling with very low risk of oedema <sup>(2)</sup>. The effect of the injection is immediately visible and enduring over time.
- An ideal viscoelastic profile which makes injection of the gel easier for a more controlled application of the product, while providing high spreading capability and an optimal positioning for a natural and homogenous correction.
- → Specific mechanical properties which induce a light gel which exerts
  low pressure on the tissues, also contributing to a reduced risk of
  oedema<sup>(2)</sup>.

Redensity [II] Eyes innovation also includes a combination of hyaluronic acid with a dermo-restructuring complex as well as lidocaine, a local anaesthetic added to provide comfort to the patient during treatment sessions.

#### SEMI-CROSSLINKED HYALURONIC ACID 15 mg/g

Combination of cross-linked\* HA (BDDE) and non cross-linked HA

# DERMO-RESTRUCTURING COMPLEX\*\*

8 amino acids, 3 antioxidants, 2 minerals and 1 vitamin



LIDOCAINE

TEOSYAL PURESENSE

# Redensity [II] Eyes



## TEOXANE INNOVATION

# A unique formulation specifically designed for eye circles

# CLINICAL RESULTS

An evaluative clinical trial <sup>(2)</sup> was carried out on 67 patients (55 women and 12 men) specifically seen to have eye circles. Follow-up was carried out during 6 successive examinations over the course of a year: at injection stage, after 14-days, then at 1-month, 3-month, 6-month and 12-month check-ups. Evaluation criteria were as follows: efficiency acknowledged by physicians according to the Global Aesthetic Improvement Scale (GAIS) with regard to wrinkle, texture, radiance, tonus and hydration parameters, patient satisfaction and tolerance, which was assessed in relation to side effects described by patients at each examination session.

### **⊕** EFFICIENCY

- Half of patients said they were satisfied of the results immediately after injection, at 6 months and until 1 year and would recommend the treatment to their close relation.
- Investigators as well as patients noted a real improvement at up to 1 month and 3 months according to the following parameters: skin texture, elasticity, redensification, filling. Corrections were evaluated as natural and homogenous.

### SAFETY

- Redensity [II] Eyes tolerance was tested using an injected average volume of 0.37 ml per eye circle (the recommended dose is 0.50 ml maximum per eye circle).
- Out of 67 patients, only 4 cases showed transitional side effects were noted. Redness and post-injection bruises disappeared within 72 hrs after injection, 1 case of oedema was recorded, which resorbed spontaneously within a month, and no Tyndall effect was observed.

#### **EASE OF USE**

• 81% of physicians esteem the product to be easy to inject and position.

This evaluation clinical trial lead to the procurement of the Redensity [II] Eyes indication and the CE marking Class III, certified by BSI\*. Redensity [II] Eyes is now registered in over 60 countries (Europe, Russia, Asia, Latin America, Middle-East, Canada) with its main indication being the treatment of the periorbital area.





# KNOWLEDGE AND KNOW-HOW

TEOXANE Laboratories is a Swiss group with international scope and expertise in aesthetic medicine. Established in 2003 in Geneva, it specialises in the design and manufacture of hyaluronic acid-based injectable implants. The first fillers, released on the market in 2004, were immediately successful and opened the way to the development of a full range of products responding precisely to the needs and characteristics of each anatomical area.

The range of products made of 100% non-animal origin resorbable hyaluronic acid combines Safety, Efficacy and Durability. Thanks to the brand's three core values Teoxane products are recognized for their quality and have enabled it to be propelled to the third place in the world ranking of hyaluronic acid-based filling implant manufacturers. With 10 years of clinical experience behind it, Teoxane Laboratories is now recognized by aesthetic physicians, dermatologists and plastic surgeons in over 90 countries worldwide.

# ONGOING TRAINING AND SUPPORT

As with other products in the Teosyal® range, the launch of Redensity [II] Eyes was accompanied by specific medical training allowing specialised physicians to learn how to use the product properly, in addition to related injection techniques. Furthermore, an international day, the Teosyal Expert Day, was recently dedicated to Redensity [II] Eyes and to the specific care of the suborbital area. This information and training day aimed at exchanging good practices in aesthetic medicine amongst the best international experts. Over 300 practitioners attended the meeting last October.


In order to best support the physicians in their practice, as well as patients in search of treatments, Teoxane Laboratories provides a medical information service which collates questions, observations and follow-up on potential side-effects.





# Redensity [II] Eyes





Estimated duration: 12 months minimum

Injection area: Deep supra-periosteal and under the orbicularis muscle

<sup>\*</sup>From the patented technology RHA : Resilient Hyaluronic Acid™

<sup>\*\*</sup> Patent pending technology.

TEOSYAL PURESENSE

# Redensity [II] Eyes



# A UNIQUE FORMULATION SPECIFICALLY DESIGNED FOR EYE CIRCLES

Teosyal® PureSense Redensity [II] Eyes has been developed from an innovative production process that results in a subtle balance between a 15mg/g concentration level of hyaluronic acid and a semi-crosslinked preparation.

This sophisticated formulation contains the relevant properties to correct the eye circle region: a low hygroscopic activity, an ideal viscoelastic profile and specific mechanical properties allow natural, long-lasting and controlled correction without swelling and with very low risk of oedema.

## **→ A SPECIFIC INJECTION TECHNIQUE**

Treating eye circles is a delicate matter; therefore all practitioners wishing to inject Teosyal® PureSense Redensity [II] Eyes must be specifically trained to practice the injection technique.

It is indeed essential:

- To precisely know the anatomical area: a thin skin that puffs rapidly and a richly vascularized area with a significant bundle of suborbital nerves.
- To properly assess indications for treatment: the patient must be seated in a semi-reclined position while the diagnosis and evaluation of their eye circles are made.
- To perfectly master the cannula or needle techniques: the injection needs to be done slowly, deeply, upon contact with the bone and using only a small quantity of product.

#### RESULTS

BEFORE Immediately after injection

Provided that the provided of the provided

#### TEOSYAL PURESENSE

# Redensity [II] Eyes



# Questions / Answers

#### Can Teosyal® PureSense Redensity (II) Eyes be injected into all circles?

The product indication is very specific: it is only suitable for eye circles and minimal palpebral bags, without loosening of the eyelid or lymphatic stasis. Teosyal® PureSense Redensity [II] Eyes is not recommended for pigmentary dark circles or significant fat bags around the eyes, for the latter surgery would be suggested. Following a specialized and personalized consultation, an injection in this area may balance eyelid volume in cases of minimal fat projections.

Note: in the event a patient has been previously treated with a permanent filling product (calcium hydroxyapatite, poly-L-lactic acid) in the eye circle, the injection is contraindicated.

#### Does it leave marks on the skin?

Redness and small bruises may appear at the site of injection, but they can be significantly reduced when applying an ice pack after injection and easily hidden. They usually disappear after 72 hrs. In most cases, there is no oedema.

#### Is a touch-up session necessary?

No, in 72% of cases, it isn't necessary\*. Only significant eye circles may require a further injection, which can be performed a month later.

#### What is the product's lifetime?

12 months minimum. However, the low presence of hyaluronidase (enzymes degrading hyaluronic acid) in this area makes the product more enduring than on other injection sites. The result might therefore last up to 24 months.

#### • Does the product allow smoothing out of fine lines on the bottom eyelid?

Fine lines won't disappear but the injections of Teosyal® PureSense Redensity [II] Eyes may soften them as the product retightens the skin slightly. The dermo-restructuring complex also reinforces this action.

#### Is it possible to inject other filling products the same day? Botulinum toxin?

The injection of hyaluronic acid volumizing implants is possible in the cheekbone and cheek area, but it is preferable to avoid any other injection the same day. Corrections on the facial contour are, however, contraindicated in order not to overwork the lymphatic system. Botulinum toxin is a different matter; it is absolutely not recommended to inject botulinum toxin simultaneously with other filling products that concern the same anatomical areas.

#### • Who is authorized to inject Teosyal® PureSense Redensity (II) Eyes?

All practitioners (aesthetic physicians, dermatologists, plastic surgeons, ophthalmologists etc.) trained in eye circle injection techniques.

#### Are there competitor products to Teosyal® PureSense Redensity (II) Eyes?

There are competitor products, however Teosyal® PureSense Redensity [II] Eyes is the only filler specifically indicated for eye circles.

\* Clinical evaluation study carried out on 67 patients, followed-up over one year (2010) and leading to the procurement of the CE marking.

